Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269236 | 0.87 | KMT2A (0.48) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1269332 | 0.87 | RAB9A (0.52) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1269351 | 0.79 | KMT2A (0.47) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1268291 | 0.75 | L3MBTL1 (0.49) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1269139 | 0.75 | L3MBTL1 (0.49) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1268302 | 0.73 | KMT2A (0.47) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1269375 | 0.73 | KMT2A (0.47) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1269229 | 0.73 | MAPK1 (0.50) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1269302 | 0.72 | KMT2A (0.47) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL1268419 | 0.72 | KMT2A (0.47) | KMT2ASMN1; SMN2ALOX15RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | KMT2A 575/4885SMN1; SMN2 865/4885ALOX15 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.